These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37631064)

  • 1. Therapeutic Potential of Cannabinoids in Glaucoma.
    Lindner T; Schmidl D; Peschorn L; Pai V; Popa-Cherecheanu A; Chua J; Schmetterer L; Garhöfer G
    Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The arguments for and against cannabinoids application in glaucomatous retinopathy.
    Panahi Y; Manayi A; Nikan M; Vazirian M
    Biomed Pharmacother; 2017 Feb; 86():620-627. PubMed ID: 28027538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Endocannabinoid System as a Therapeutic Target in Glaucoma.
    Cairns EA; Baldridge WH; Kelly ME
    Neural Plast; 2016; 2016():9364091. PubMed ID: 26881140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids in Glaucoma Patients: The Never-Ending Story.
    Passani A; Posarelli C; Sframeli AT; Perciballi L; Pellegrini M; Guidi G; Figus M
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33302608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
    Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
    Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids in the treatment of glaucoma.
    Järvinen T; Pate DW; Laine K
    Pharmacol Ther; 2002 Aug; 95(2):203-20. PubMed ID: 12182967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure.
    Miller S; Daily L; Dharla V; Gertsch J; Malamas MS; Ojima I; Kaczocha M; Ogasawara D; Straiker A
    Exp Eye Res; 2020 Dec; 201():108266. PubMed ID: 32979397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in glaucoma.
    Vishwaraj CR; Kavitha S; Venkatesh R; Shukla AG; Chandran P; Tripathi S
    Indian J Ophthalmol; 2022 Feb; 70(2):380-385. PubMed ID: 35086201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids as New Drug Candidates for the Treatment of Glaucoma.
    Jordan E; Nguyen GN; Piechot A; Kayser O
    Planta Med; 2022 Nov; 88(14):1267-1274. PubMed ID: 35299275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sigma-1 receptor agonist, (+)-pentazocine, is neuroprotective in a Brown Norway rat microbead model of glaucoma.
    Mysona BA; Zhao J; De Greef O; Beisel A; Patel PA; Berman L; Smith SB; Bollinger K
    Exp Eye Res; 2023 Jan; 226():109308. PubMed ID: 36400283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cannabinoid applications in glaucoma].
    Pinar-Sueiro S; Rodríguez-Puertas R; Vecino E
    Arch Soc Esp Oftalmol; 2011 Jan; 86(1):16-23. PubMed ID: 21414525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of potential novel glaucoma therapeutic options independent of intraocular pressure.
    Shalaby WS; Ahmed OM; Waisbourd M; Katz LJ
    Surv Ophthalmol; 2022; 67(4):1062-1080. PubMed ID: 34890600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.
    Kokona D; Georgiou PC; Kounenidakis M; Kiagiadaki F; Thermos K
    Neural Plast; 2016; 2016():8373020. PubMed ID: 26881135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.
    Miller S; Kulkarni S; Ciesielski A; Nikas SP; Mackie K; Makriyannis A; Straiker A
    Pharmaceuticals (Basel); 2018 May; 11(2):. PubMed ID: 29786643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the endothelin A (ET
    McGrady NR; Minton AZ; Stankowska DL; He S; Jefferies HB; Krishnamoorthy RR
    BMC Neurosci; 2017 Mar; 18(1):27. PubMed ID: 28249604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of applying cannabinoids' in the treatment of glaucoma].
    Nadolska K; Goś R
    Klin Oczna; 2008; 110(7-9):314-7. PubMed ID: 19112869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
    García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspective of neuroprotection and glaucoma.
    Tian K; Shibata-Germanos S; Pahlitzsch M; Cordeiro MF
    Clin Ophthalmol; 2015; 9():2109-18. PubMed ID: 26635467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.